triple glp 1 agonist New strategies for the treatment of obesity and metabolic dysfunctions Why target one pathway when

CMC Weight Loss is helping patients with GLP-1 options utilizing Medicare initiatives that make life-changing medications more affordable.

Designed to complement your GLP-1 journey

Clostridium butyricum produces the postbiotic butyrate which stimulates GLP-1. Bifidobacterium infantis produces the postbiotic acetate, and interacts with Akkermansia and Butyricum to promote an ecosystem in the gut that naturally boosts GLP-1

Mounjaro and Zepbound are now out of shortage

GLP-1RAs reduce events linked to atherogenic cardiovascular disease (especially ischemic stroke) and also renal outcomes (FLOW trial with semaglutide), with a limited effect on heart failure

Imagine designing a medication trial hoping to demonstrate one benefitand then finding out that your study drug just happens to have significant additional health benefits